Bailard’s MacroGenics MGNX Stock Holding History

Bailard’s Portfolio MGNX Stock Details MGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-12,600	Closed	-$270K	–	530
2018 Q3	$270K	Buy	+12,600	New	+$269K	0.02%	481
2017 Q2	–	Sell	-44,000	Closed	-$818K	–	292
2017 Q1	$818K	Buy	+44,000	New	+$849K	0.07%	186

Other funds holding MGNX

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CPV Partners Stamford, Connecticut $224M AUM 77.2% 1-Year Est. Return

IVM

InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Bailard's MGNX Position: Q4 2018 in Review

Bailard sold out of MacroGenics (MGNX) in Q4 2018, closing a stake of 12,600 shares — an estimated $270K sold.

Bailard first reported a position in MGNX in Q1 2017 and held it in 2 quarters. The position peaked at $818K in Q1 2017. 133 funds tracked by Wall St. Rank hold MGNX as of Q4 2018.

Bailard reported no remaining MacroGenics position as of Q4 2018 after selling out during the quarter.
Bailard sold 12,600 MacroGenics shares in Q4 2018, an estimated $270K.
Bailard first reported a position in MacroGenics in Q1 2017 and held it in 2 quarters.
Bailard's MacroGenics position peaked at $818K in Q1 2017.
133 funds tracked by Wall St. Rank held MacroGenics as of Q4 2018.

Based on Bailard's 13F filing for Q4 2018, filed 5 Feb 2019.